CTIX Discussion Topics 08/19/2014 17:27:01 $CTIX
NR, this is all very true. Only because you didn't mention it, do you have a target value for partnership(s).
Good analysis. I reckon you called the near term CTIX price action this time again, as so often in the past. The coming days will tell.
Medium term, undoubtedly we are looking at CTIX share price gains on positive news. I reckon there will be an additional share price run-up just on the rumour, ahead of the news.
This time around for CTIX it could be Buy the Rumour and Buy the News. Which if it occurs, will be a welcome change.
Good times ahead for CTIX longs and rally traders I reckon.
CTIX Stock Message Board http://investorshangout.com/Cellceutix-Corpor...TIX-87375/
Quote:
Where is that Prurisol final report? It was due last Friday per Mr. Ehrlich.
LEO told Wild we would receive an update on ALL our trials by the end of August. I'm pretty sure that includes Kevetrin.
Stay tuned.
I damn sure wouldn't want to be out when LEO announces R&R through a PR and the word Kevetrin is finally uttered by Menon for the first time this year!!.
Quote:
WATCH OUT ' There,s that $1.80 AGAIN?!! The scavengers never quit eom gov
R&R - K update. P21 data. B update. B data.
We're far enough along in both these trials that this is a real possibility.
Expectations driven by sound fundamentals. That's what's moving our SP up IMO.
Leo should be announcing R&R any day. What news will accompany that PR?
We're not done moving up just yet
NR yes to news changes all. Not going to sell a share till major price accumulation, but thats hoe I view this one.
Short-term there is likely to be a pullback. This is the 5th time that RSI has reached 80 since 1/2010. It just does not stay in this range for very long. The day of peak volume or one day later the sp topped in each case. I would love to see us close at $2.10 or above, but the rally weakened a bit today and I'm not sure we will make it. Will we have even more volume tomorrow? If we were to get above $2.10 we would establish a new pattern of higher highs and higher lows. News, of course, changes everything.
We did have two sustained periods of RSI above 70 and sp fluctuating but up nicely over the whole period. See my post on that from yesterday.
Medium term (through year-end) the trend will be up, depending of course on the news of cohort progression, B equivalence, and Prurisol Phase 2/3. Positive reports from any one of these and we are higher at year-end.
Where is that Prurisol final report? It was due last Friday per Mr. Ehrlich.
WATCH OUT ' There,s that $1.80 AGAIN?!! The scavengers never quit eom gov
Thanks for stopping by Tom. Always appreciate your insight.
App.
123tom, I still try and keep my emotions in check. Still have my mental stop in place. Been raising it as the price has been going up. But, you are correct:
Quote:
... nothing wrong with taking some profit ...
Question will be, when is right?
For real long term holders, not even close. And, I see things much as many of them do from a long term view. Then, I have my trading account; and in this account, I preserve profits and protect capital.
My trading account is much more sensitive than my long term account. The long term account has done well for me too.
Hats Off to Leo:
in a little over a year he has taken Brilacidin from the dredges of bankruptcy court to completed enrollment in a decent sized phase 2 B study.
The drug is a novel class of antibiotic with no documented ability for antibiotic resistance.
One dose may stop MRSA in 95% of patients.
Hail LEO !!!
Nice summary ,INHelp, I agree with it.
I might watch out for that late money coming in from sheeple climbing into the late bubbling , thats a sure sign of impending selling by smart sellers at the top zone. you always see that big volume at the end of a rally wave.
not yet, thats right, not yet.
this could pop some more. but nothing wrong with taking some profit around the 2.40 retest area. like you said, upon a bunch of fails to traverse higher.
sounds right to me.
maybe a pullback chance if it falls back to 1.80 ??
Great breakdown as always TOB! Thank you
123tom, just looking at the chart, and it is a bit scary, overbought.
There are a few things preventing me from selling right here:
1) Volume is too good. Confirms the move is strong. Has been increasing on already way above average volume.
2) Trade has not gotten overheated. Especially today. Good consolidation. Good backfilling. Still green.
3) Have not seen the usual topping unsustainable parabolic move yet. Although the chart is pretty vertical .
4) There appears to be continuing Smart Money accumulation. Still see evidence of buying above the Ask, from time to time. Tells me, someone thinks this is still bargain priced.
I am still mostly trying to follow Smart Money, without reacting too quickly on the tick by tick. Still don't see a whole lot of evidence for strong retailer participation.
Our next hurdle will be to break $2. Right there, right now. If several attempts are made, and they fail, and volume drops off, I will call a short term, tradable resistance top.
If there is an unsustainable parabolic move upwards, I will call a short term, tradable top.
Any strong resistance point upwards through $2.45 in which several attempts are made, and fail, with falling volume, I will call a short term, tradable top
If $2.45 breaks (approx.), all bets are off, because we get into uncharted new highs, and there could be a major move higher. No built up resistance above this level.
Regardless of short term tops, I think CTIX may finally be getting into a bullish transcending pattern, which could be of long term duration.
Trade carefully.
CTIX Daily Chart
Today saw a small bodied green candle continuing the three day parabolic portion of the rally off of the recent low at 1.60.
The day opened strong, and five minutes into the day saw the highest volume 1 min bar 136,413 shares traded from 2.00 to the 2.01 HOD
The price declined to 1.91, back to 1.98, down to 1.91 again and then ping pong back to 2.01 with all of the price action above 1.96 from 8:57am CT onward.
A volume increase with some strong action into the close, but much lower than the morning buying volume.
As we see, the magenta line is resistance at 1.96 which could be morphing into new support. Generally my work requires three days closing above resistance to call it new support, or a strong move through higher resistance lines.
CTIX pierced, and closed for the day right at the next minor resistance level at 1.99, however, round number psychological resistance is likely at play here, and thus the 'true' resistance ceiling today. HOD just a penny higher at 2.01
The small bodied bar could well indicate some topping, as mentioned earlier by noretreat, with a pullback, or consolidation here... but, we are close to catalysts so upside follow through is also possible.
It all depends on how many shares are for sale at ~2.00 , and how much buying pressure occurs. After 7 months of waiting, selling at 2.00 may have some attraction, but considering the upcoming catalysts, I expect it won't be too very long before we talk about 2.00 as support instead of resistance.
JMO, only time will tell... a more confident opinion is below the two charts.
CTIX Daily Chart, click to enlarge, scroll down for 1 minute chart
Today's CTIX 1 minute chart
.
Rally Monkey says "Shut up wi di charts and BUY BUY BUY"
CTIX chart...what do you technical chart analysts see here.
I'm tending to see the same thing ,Noretreat,
careful here. and any more surging with new investors, newcomers late into the rally is always a topping sign, waiting to get sold off. Ive been seeing that 2.45 top zone as a target that a tired rally could retest. the bubbling momentum could jump in and take price there, and get smashed down by smart profit takers. in a Range top zone 2.15-2.45
at the same time, a greater long term chart wave pattern can describe this long sideways slide this past year as a Wave 4, and we could see the next rally, maybe starting now, as a Wave 5. which could target closer to 2.45-3.00 area before its finished.
weekly chart
http://stockcharts.com/c-sc/sc?s=CTIX&p=W...8479784393
daily chart...and yep, that RSI and Stochastic is way overbought. the weekly is getting up there soon.
http://stockcharts.com/c-sc/sc?s=CTIX&p=D...8479974045
SOME GOODIES!
Quote:
Many new drugs demonstrate toxicity immediately, so I interpret the information on Kevetrin™ with a great deal of optimism. We are excited for the upcoming weeks when the next cohort, in which dosing levels will be doubled, may provide us even greater insight on what we believe is the most exciting oncologic drug in development today.
” - See more at: http://cellceutix.com/cellceutix-anti-cancer-...5n40W.dpuf
Quote:
The facts are while other compounds mentioned are not yet in clinical trials, or ready for clinical trials, our flagship p53 compound, Kevetrin is currently in phase 1 trials ongoing at Harvard’s Dana-Farber Cancer Institute and Beth Israel Deaconess Medical Center. I believe that a discerning examination of the article and publicly available information shows that we are not only ahead of these larger companies, but we have a better mechanism which is more likely to function against most cancers. Our research to date shows that Kevetrin affects both wild and mutant types of p53, a claim that to the best of our understanding, the other companies cannot make. It is true that Roche has had Nutlins in clinical trials for years, but has faced ongoing challenges. Our data shows that Kevetrin is non-genotoxic, meaning that it does not damage surrounding normal DNA.”
“As we stated in a press release on April 25, 2011 discussing our poster presentation at last year’s annual meeting of the American Association for Cancer Research, Kevetrin was a standout then amongst any other p53 drug in development,” added Dr. Krishna Menon, Chief Scientific Officer of Cellceutix. “Nothing has fundamentally changed since that day. In fact, the additional laboratory data that we have collected on Kevetrin, reinforces the novel drug’s ability to re-activate p53 to its role as a potent anti-proliferative and pro-apoptotic protein and holds a great deal of promise as a new therapeutic for treating cancer including some of the most difficult to treat types of the disease. The New York Times may have overlooked Cellceutix and Kevetrin, but the organizations that are contacting us to host and sponsor clinical trials certainly have not.”
- See more at: http://cellceutix.com/cellceutix-comments-on-...PrNkH.dpuf
Quote:
“We are excited by the advancement of the clinical trials of Kevetrin as we move toward finding the MTD (maximum tolerated dose),” said Dr. Krishna Menon, Chief Scientific Officer of Cellceutix. “While we are still early in the trials, we are eager to receive information on the p21 biomarker as it could represent a major breakthrough in cancer research. There has been no shortage of commentary and discussions in the scientific community recently about the latest initiatives of the U.S. Food and Drug Administration to further expedite novel drugs to market for areas of great unmet medical need. Obviously, we will be exploring this option for Kevetrin, however an application for this type of rapid movement through the regulatory process can only be made after the completion of the phase 1 clinical study.”
- See more at: http://cellceutix.com/cellceutix-reports-on-k...FgGB7.dpuf
Quote:
“We are going to continue aggressively moving forward with Brilacidin as the current biotechnology environment is desperate for new therapeutics,” added Leo Ehrlich, Chief Executive Officer at Cellceutix. ”Reuters reported only yesterday that Swiss drugmaker Roche is poised to get back into antibiotics because of a novel drug that they want to develop to tackle drug-resistant bacteria. Simply, a novel drug has phenomenal sales potential. Johnson & Johnson’s Levaquin was generating $1.3 billion in sales before it came off patent. Cubist’s Daptomycin for ABSSSI only comprised 8 percent of total doses, yet controlled approximately 82 percent of total sales in that market. The majority of approved antibiotics today are legacy drugs or variations of them for which resistance is constantly evolving. Our plan is to establish Brilacidin as the next generation antibiotic. It has opened a door to a multi-billion-dollar pathway and we are not just looking at it, we are part way through it and moving as quickly as possible to establish a leadership position.”
- See more at: http://cellceutix.com/cellceutix-to-pursue-si...VAaqr.dpuf
Quote:
“The alarms have sounded globally, signaling the dire need for new antibiotics and the premium prices that promising compounds can command. Roche recently jumped back into the antibiotic markets by agreeing to pay up to $548 million for a Phase II antibiotic targeting Gram-negative pathogens,” said Dr. Krishna Menon, Chief Scientific Officer at Cellceutix. “We believe there is a great interest in the pharmaceutical industry for clinical-stage gram-negative compounds. We are extremely motivated to move the drugs forward as quickly as possible to statisfy this interest. The latest research with PMX1502 and PMX1408 well positions us to move into the multi-billion-dollar anti-fungal and Gram-negative bacterium markets. We knew we were gaining substantial assets with the PolyMedix acquisition, but this is evolving into more than even I expected at this point.”
- See more at: http://cellceutix.com/cellceutix-identifies-d...GPKET.dpuf
Quote:
Entering the conference, the Company believed that Brilacidin for a single indication such as Acute Bacterial Skin and Skin Structure Infections (ABSSSI) would conservatively have a market potential slightly above $100 million annually should it eventually garner U.S. Food and Drug Administration approval. Following a week of meeting with other biotechnology companies, investment bankers and analysts, the Company realized that it was significantly undervaluing its estimation of the potential value of Brilacidin for ABSSSI. Several factors influenced the determination, including the dire need for new antibiotics that have not yet developed resistance and are less likely to develop resistance, recent changes in reimbursement policies and an ongoing shift to encourage cost-effective therapies, which is supportive of single-dose treatments, such as two of the dosing regimens in the upcoming Phase 2b trial of Brilacidin. The Company sees reduced reimbursement for the other competing drugs for ABSSSI that have already developed resistance and a higher reimbursement for a drug like Brilacidin, which is needed for patients who have resistance to existing antibiotics. Further, reimbursement is expected to be higher for drugs that prevent serious illness or death and for those where there is no alternative treatment
. - See more at: http://cellceutix.com/cellceutix-sees-increas...5wCDm.dpuf
Quote:
Due to the unique properties of Brilacidin as a defensin mimetic and a possible one-time or even a three-day drug treatment to patients, we see an FDA approved Brilacidin for ABSSSI having the potential to knock off the present market leader who is presently generating approximately $1,000,000,000 in yearly sales.
- See more at: http://cellceutix.com/cellceutix-selects-dr-r...U1l2G.dpuf
smitter, it was a nice consolidation day, and a green one.
Your post:
Quote:
Best consolidation and loading at this lever than any other previous attempt to crack $2.00.
If she breaks it this time and holds we could see $2.15-$2.30 very quickly....
$2.00 was a major support/resistance level the last time round. We got lots of the heavy lifting done today, with volume of 940,106.
Third consecutive white candle day, and each day with above average and increasing volume.
Really liked todays trading. Did not get overheated. Lots of backfilling. Sustainable gain. Good launching pad for the test on $2 tomorrow.
NITE was playing games with a 30K ASK and then dropping to a 100 Ask on 1.99 removing the 30K....back and forth trying to keep a lid at 2
All of this is just building a great support launching pad. Hopefully whoever is buying 10-20K at a time is holding for Long.
NR, this is all very true. Only because you didn't mention it, do you have a target value for partnership(s).
Good analysis. I reckon you called the near term CTIX price action this time again, as so often in the past. The coming days will tell.
Medium term, undoubtedly we are looking at CTIX share price gains on positive news. I reckon there will be an additional share price run-up just on the rumour, ahead of the news.
This time around for CTIX it could be Buy the Rumour and Buy the News. Which if it occurs, will be a welcome change.
Good times ahead for CTIX longs and rally traders I reckon.
CTIX Stock Message Board http://investorshangout.com/Cellceutix-Corpor...TIX-87375/
Quote:
Where is that Prurisol final report? It was due last Friday per Mr. Ehrlich.
LEO told Wild we would receive an update on ALL our trials by the end of August. I'm pretty sure that includes Kevetrin.
Stay tuned.
I damn sure wouldn't want to be out when LEO announces R&R through a PR and the word Kevetrin is finally uttered by Menon for the first time this year!!.
Quote:
WATCH OUT ' There,s that $1.80 AGAIN?!! The scavengers never quit eom gov
R&R - K update. P21 data. B update. B data.
We're far enough along in both these trials that this is a real possibility.
Expectations driven by sound fundamentals. That's what's moving our SP up IMO.
Leo should be announcing R&R any day. What news will accompany that PR?
We're not done moving up just yet
NR yes to news changes all. Not going to sell a share till major price accumulation, but thats hoe I view this one.
Short-term there is likely to be a pullback. This is the 5th time that RSI has reached 80 since 1/2010. It just does not stay in this range for very long. The day of peak volume or one day later the sp topped in each case. I would love to see us close at $2.10 or above, but the rally weakened a bit today and I'm not sure we will make it. Will we have even more volume tomorrow? If we were to get above $2.10 we would establish a new pattern of higher highs and higher lows. News, of course, changes everything.
We did have two sustained periods of RSI above 70 and sp fluctuating but up nicely over the whole period. See my post on that from yesterday.
Medium term (through year-end) the trend will be up, depending of course on the news of cohort progression, B equivalence, and Prurisol Phase 2/3. Positive reports from any one of these and we are higher at year-end.
Where is that Prurisol final report? It was due last Friday per Mr. Ehrlich.
WATCH OUT ' There,s that $1.80 AGAIN?!! The scavengers never quit eom gov
Thanks for stopping by Tom. Always appreciate your insight.
App.
123tom, I still try and keep my emotions in check. Still have my mental stop in place. Been raising it as the price has been going up. But, you are correct:
Quote:
... nothing wrong with taking some profit ...
Question will be, when is right?
For real long term holders, not even close. And, I see things much as many of them do from a long term view. Then, I have my trading account; and in this account, I preserve profits and protect capital.
My trading account is much more sensitive than my long term account. The long term account has done well for me too.
Hats Off to Leo:
in a little over a year he has taken Brilacidin from the dredges of bankruptcy court to completed enrollment in a decent sized phase 2 B study.
The drug is a novel class of antibiotic with no documented ability for antibiotic resistance.
One dose may stop MRSA in 95% of patients.
Hail LEO !!!
Nice summary ,INHelp, I agree with it.
I might watch out for that late money coming in from sheeple climbing into the late bubbling , thats a sure sign of impending selling by smart sellers at the top zone. you always see that big volume at the end of a rally wave.
not yet, thats right, not yet.
this could pop some more. but nothing wrong with taking some profit around the 2.40 retest area. like you said, upon a bunch of fails to traverse higher.
sounds right to me.
maybe a pullback chance if it falls back to 1.80 ??
Great breakdown as always TOB! Thank you
123tom, just looking at the chart, and it is a bit scary, overbought.
There are a few things preventing me from selling right here:
1) Volume is too good. Confirms the move is strong. Has been increasing on already way above average volume.
2) Trade has not gotten overheated. Especially today. Good consolidation. Good backfilling. Still green.
3) Have not seen the usual topping unsustainable parabolic move yet. Although the chart is pretty vertical
. 4) There appears to be continuing Smart Money accumulation. Still see evidence of buying above the Ask, from time to time. Tells me, someone thinks this is still bargain priced.
I am still mostly trying to follow Smart Money, without reacting too quickly on the tick by tick. Still don't see a whole lot of evidence for strong retailer participation.
Our next hurdle will be to break $2. Right there, right now. If several attempts are made, and they fail, and volume drops off, I will call a short term, tradable resistance top.
If there is an unsustainable parabolic move upwards, I will call a short term, tradable top.
Any strong resistance point upwards through $2.45 in which several attempts are made, and fail, with falling volume, I will call a short term, tradable top
If $2.45 breaks (approx.), all bets are off, because we get into uncharted new highs, and there could be a major move higher. No built up resistance above this level.
Regardless of short term tops, I think CTIX may finally be getting into a bullish transcending pattern, which could be of long term duration.
Trade carefully.
CTIX Daily Chart
Today saw a small bodied green candle continuing the three day parabolic portion of the rally off of the recent low at 1.60.
The day opened strong, and five minutes into the day saw the highest volume 1 min bar 136,413 shares traded from 2.00 to the 2.01 HOD
The price declined to 1.91, back to 1.98, down to 1.91 again and then ping pong back to 2.01 with all of the price action above 1.96 from 8:57am CT onward.
A volume increase with some strong action into the close, but much lower than the morning buying volume.
As we see, the magenta line is resistance at 1.96 which could be morphing into new support. Generally my work requires three days closing above resistance to call it new support, or a strong move through higher resistance lines.
CTIX pierced, and closed for the day right at the next minor resistance level at 1.99, however, round number psychological resistance is likely at play here, and thus the 'true' resistance ceiling today. HOD just a penny higher at 2.01
The small bodied bar could well indicate some topping, as mentioned earlier by noretreat, with a pullback, or consolidation here... but, we are close to catalysts so upside follow through is also possible.
It all depends on how many shares are for sale at ~2.00 , and how much buying pressure occurs. After 7 months of waiting, selling at 2.00 may have some attraction, but considering the upcoming catalysts, I expect it won't be too very long before we talk about 2.00 as support instead of resistance.
JMO, only time will tell... a more confident opinion is below the two charts.
CTIX Daily Chart, click to enlarge, scroll down for 1 minute chart
Today's CTIX 1 minute chart
.
Rally Monkey says "Shut up wi di charts and BUY BUY BUY"
CTIX chart...what do you technical chart analysts see here.
I'm tending to see the same thing ,Noretreat,
careful here. and any more surging with new investors, newcomers late into the rally is always a topping sign, waiting to get sold off. Ive been seeing that 2.45 top zone as a target that a tired rally could retest. the bubbling momentum could jump in and take price there, and get smashed down by smart profit takers. in a Range top zone 2.15-2.45
at the same time, a greater long term chart wave pattern can describe this long sideways slide this past year as a Wave 4, and we could see the next rally, maybe starting now, as a Wave 5. which could target closer to 2.45-3.00 area before its finished.
weekly chart
http://stockcharts.com/c-sc/sc?s=CTIX&p=W...8479784393
daily chart...and yep, that RSI and Stochastic is way overbought. the weekly is getting up there soon.
http://stockcharts.com/c-sc/sc?s=CTIX&p=D...8479974045
SOME GOODIES!
Quote:
Many new drugs demonstrate toxicity immediately, so I interpret the information on Kevetrin™ with a great deal of optimism. We are excited for the upcoming weeks when the next cohort, in which dosing levels will be doubled, may provide us even greater insight on what we believe is the most exciting oncologic drug in development today.
” - See more at: http://cellceutix.com/cellceutix-anti-cancer-...5n40W.dpuf
Quote:
The facts are while other compounds mentioned are not yet in clinical trials, or ready for clinical trials, our flagship p53 compound, Kevetrin is currently in phase 1 trials ongoing at Harvard’s Dana-Farber Cancer Institute and Beth Israel Deaconess Medical Center. I believe that a discerning examination of the article and publicly available information shows that we are not only ahead of these larger companies, but we have a better mechanism which is more likely to function against most cancers. Our research to date shows that Kevetrin affects both wild and mutant types of p53, a claim that to the best of our understanding, the other companies cannot make. It is true that Roche has had Nutlins in clinical trials for years, but has faced ongoing challenges. Our data shows that Kevetrin is non-genotoxic, meaning that it does not damage surrounding normal DNA.”
“As we stated in a press release on April 25, 2011 discussing our poster presentation at last year’s annual meeting of the American Association for Cancer Research, Kevetrin was a standout then amongst any other p53 drug in development,” added Dr. Krishna Menon, Chief Scientific Officer of Cellceutix. “Nothing has fundamentally changed since that day. In fact, the additional laboratory data that we have collected on Kevetrin, reinforces the novel drug’s ability to re-activate p53 to its role as a potent anti-proliferative and pro-apoptotic protein and holds a great deal of promise as a new therapeutic for treating cancer including some of the most difficult to treat types of the disease. The New York Times may have overlooked Cellceutix and Kevetrin, but the organizations that are contacting us to host and sponsor clinical trials certainly have not.”
- See more at: http://cellceutix.com/cellceutix-comments-on-...PrNkH.dpuf
Quote:
“We are excited by the advancement of the clinical trials of Kevetrin as we move toward finding the MTD (maximum tolerated dose),” said Dr. Krishna Menon, Chief Scientific Officer of Cellceutix. “While we are still early in the trials, we are eager to receive information on the p21 biomarker as it could represent a major breakthrough in cancer research. There has been no shortage of commentary and discussions in the scientific community recently about the latest initiatives of the U.S. Food and Drug Administration to further expedite novel drugs to market for areas of great unmet medical need. Obviously, we will be exploring this option for Kevetrin, however an application for this type of rapid movement through the regulatory process can only be made after the completion of the phase 1 clinical study.”
- See more at: http://cellceutix.com/cellceutix-reports-on-k...FgGB7.dpuf
Quote:
“We are going to continue aggressively moving forward with Brilacidin as the current biotechnology environment is desperate for new therapeutics,” added Leo Ehrlich, Chief Executive Officer at Cellceutix. ”Reuters reported only yesterday that Swiss drugmaker Roche is poised to get back into antibiotics because of a novel drug that they want to develop to tackle drug-resistant bacteria. Simply, a novel drug has phenomenal sales potential. Johnson & Johnson’s Levaquin was generating $1.3 billion in sales before it came off patent. Cubist’s Daptomycin for ABSSSI only comprised 8 percent of total doses, yet controlled approximately 82 percent of total sales in that market. The majority of approved antibiotics today are legacy drugs or variations of them for which resistance is constantly evolving. Our plan is to establish Brilacidin as the next generation antibiotic. It has opened a door to a multi-billion-dollar pathway and we are not just looking at it, we are part way through it and moving as quickly as possible to establish a leadership position.”
- See more at: http://cellceutix.com/cellceutix-to-pursue-si...VAaqr.dpuf
Quote:
“The alarms have sounded globally, signaling the dire need for new antibiotics and the premium prices that promising compounds can command. Roche recently jumped back into the antibiotic markets by agreeing to pay up to $548 million for a Phase II antibiotic targeting Gram-negative pathogens,” said Dr. Krishna Menon, Chief Scientific Officer at Cellceutix. “We believe there is a great interest in the pharmaceutical industry for clinical-stage gram-negative compounds. We are extremely motivated to move the drugs forward as quickly as possible to statisfy this interest. The latest research with PMX1502 and PMX1408 well positions us to move into the multi-billion-dollar anti-fungal and Gram-negative bacterium markets. We knew we were gaining substantial assets with the PolyMedix acquisition, but this is evolving into more than even I expected at this point.”
- See more at: http://cellceutix.com/cellceutix-identifies-d...GPKET.dpuf
Quote:
Entering the conference, the Company believed that Brilacidin for a single indication such as Acute Bacterial Skin and Skin Structure Infections (ABSSSI) would conservatively have a market potential slightly above $100 million annually should it eventually garner U.S. Food and Drug Administration approval. Following a week of meeting with other biotechnology companies, investment bankers and analysts, the Company realized that it was significantly undervaluing its estimation of the potential value of Brilacidin for ABSSSI. Several factors influenced the determination, including the dire need for new antibiotics that have not yet developed resistance and are less likely to develop resistance, recent changes in reimbursement policies and an ongoing shift to encourage cost-effective therapies, which is supportive of single-dose treatments, such as two of the dosing regimens in the upcoming Phase 2b trial of Brilacidin. The Company sees reduced reimbursement for the other competing drugs for ABSSSI that have already developed resistance and a higher reimbursement for a drug like Brilacidin, which is needed for patients who have resistance to existing antibiotics. Further, reimbursement is expected to be higher for drugs that prevent serious illness or death and for those where there is no alternative treatment
. - See more at: http://cellceutix.com/cellceutix-sees-increas...5wCDm.dpuf
Quote:
Due to the unique properties of Brilacidin as a defensin mimetic and a possible one-time or even a three-day drug treatment to patients, we see an FDA approved Brilacidin for ABSSSI having the potential to knock off the present market leader who is presently generating approximately $1,000,000,000 in yearly sales.
- See more at: http://cellceutix.com/cellceutix-selects-dr-r...U1l2G.dpuf
smitter, it was a nice consolidation day, and a green one.
Your post:
Quote:
Best consolidation and loading at this lever than any other previous attempt to crack $2.00.
If she breaks it this time and holds we could see $2.15-$2.30 very quickly....
$2.00 was a major support/resistance level the last time round. We got lots of the heavy lifting done today, with volume of 940,106.
Third consecutive white candle day, and each day with above average and increasing volume.
Really liked todays trading. Did not get overheated. Lots of backfilling. Sustainable gain. Good launching pad for the test on $2 tomorrow.
NITE was playing games with a 30K ASK and then dropping to a 100 Ask on 1.99 removing the 30K....back and forth trying to keep a lid at 2
All of this is just building a great support launching pad. Hopefully whoever is buying 10-20K at a time is holding for Long.
